HDL: To treat or not to treat?

QR Code

HDL: To treat or not to treat?

Several studies have shown an inverse relationship between HDL cholesterol (HDL-C) levels and the risk of cardiovascular disease. Low HDL-C levels are commonly present in subjects with diabetes, metabolic syndrome, or obesity. These observations have suggested that increasing HDL concentrations migh...

Full description

Bibliographic Details
Main Authors:	Pirillo, A., Tibolla, G., Norata, Giuseppe, Catapano, A.
Format:	Journal Article
Published:	2014
Online Access:	http://hdl.handle.net/20.500.11937/55732

Similar Items

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Novel concepts in HDL pharmacology
by: Remaley, A., et al.
Published: (2014)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

Statins and skeletal muscles toxicity: From clinical trials to everyday practice
by: Norata, Giuseppe, et al.
Published: (2014)

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

Gene silencing approaches for the management of dyslipidaemia
by: Norata, Giuseppe, et al.
Published: (2013)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Impact of systemic inflammation and autoimmune diseases on apoA-i and HDL plasma levels and functions
by: Montecucco, F., et al.
Published: (2015)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

HDL and its subpopulation (HDL2 and HDL3) promote cholesterol transporters expression and attenuate inflammation in 3T3-L1 mature adipocytes induced by tumor necrosis factor-alpha
by: Suhaila Abd Muid,, et al.
Published: (2022)

HDL and its subpopulation (HDL2 AND HDL3) promote cholesterol transporters expression and attenuate inflammation in 3t3-l1 mature adipocytes induced by tumor necrosis factor-alpha
by: Suhaila Abd Muid,, et al.
Published: (2022)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

UMP hasil HDL mampu bunuh koronavirus
by: Siti Nur Azwin, Zulkapri
Published: (2020)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Prevalence of classical CD14++/CD16 - But not of intermediate CD14++/CD16 + monocytes in hypoalphalipoproteinemia
by: Sala, F., et al.
Published: (2013)

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia
by: Grigore, L., et al.
Published: (2013)

High blood pressure in acute stroke: to treat or not to treat
by: Sare, Gillian M., et al.
Published: (2007)

Design and implementation of advanced encryption standard using verilog HDL
by: Shamsiah, Suhaili, et al.
Published: (2022)

New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
by: Norata, Giuseppe, et al.
Published: (2013)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Blood pressure in acute stroke: to treat or not to treat - that is still the question
by: Bath, Philip M.W., et al.
Published: (2018)

Hymenolepis nana in a renal transplant recipient : to treat or not to treat?
by: Amin Nordin, Syafinaz, et al.
Published: (2011)

Cannot write session to /tmp/vufind_sessions/sess_bkac8h1eap7orc1ke1aav1njdm